Story
Wells Fargo Taps Annexon as Top Biotech Pick on Pipeline Potential

Wells Fargo has designated Annexon as its top pick in the biotechnology sector, highlighting a favorable risk-reward profile and significant upside potential. The investment firm's increased confidence follows recent meetings with Annexon's management and is centered on key upcoming milestones for its lead drug candidates.
Wells Fargo's Bullish Thesis
In a note to clients, Wells Fargo outlined a bull-case scenario with a potential 7-to-8 times upside for Annexon's stock. This optimistic outlook is underpinned by the potential of the company's clinical pipeline and its differentiated approach to treating certain neurodegenerative diseases.
The firm's analysis points to two primary drivers of value in the near and medium term: a late-stage drug for geographic atrophy and a planned regulatory filing for a treatment targeting Guillain-Barré syndrome.
Key Pipeline Catalysts
A central element of Wells Fargo's thesis is Annexon's lead drug candidate, vonaprument, for the treatment of geographic atrophy (GA), a leading cause of blindness. The company remains on track for a pivotal data readout that could reshape the treatment landscape for the disease.
Ad- Pivotal Data: Top-line results from the Phase 3 trial of vonaprument are expected in the fourth quarter of 2026.
- Market Potential: If successful, Wells Fargo forecasts that vonaprument could become the standard of care, with potential peak sales of approximately $4 billion.
- Mechanism: According to the note, Annexon's management emphasizes the drug's unique mechanism, which works upstream of other inhibitors and focuses on preserving photoreceptor cells essential for vision.
Wells Fargo also identified a nearer-term catalyst with tanruprubart, a treatment for Guillain-Barré syndrome (GBS). Annexon is tracking toward filing a Biologics License Application (BLA) in the U.S. before the vonaprument data release, with clinical data for tanruprubart expected in early Fall.
Analyst Context
Wells Fargo's positive assessment adds to a mixed but active analyst landscape for Annexon. Recently, Needham reiterated a Buy rating and increased its price target to $25. In contrast, Citizens initiated coverage with an Underperform rating, indicating a divergence of opinion among investment analysts on the company's valuation and prospects.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.